Poly Medicure Limited has informed the Exchange regarding re-appointment of Mr. Amit Khosla and Ms. Sonal Mattoo as Non- Executive Independent Director of the company in its Board meeting held on today i.e. 08th August, 2025, w.e.f. Conclusion of 30th Annual General Meeting of the Company.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure's board, meeting on 08 August 2025, approved the unaudited Q1 FY26 results. Standalone total income rose to ₹42,514.22 lakhs (vs ₹38,425.62 lakhs in Q1 FY25) and profit after tax grew to ₹8,792.89 lakhs (vs ₹7,230.25 lakhs), with basic EPS of ₹8.68. On a consolidated basis, total income stood at ₹44,490.16 lakhs and PAT at ₹9,308.29 lakhs (EPS ₹9.19), reflecting strong year-on-year growth. The board re-appointed Mr. Amit Khosla and Ms. Sonal Mattoo as Non-Executive Independent Directors for five years each, subject to shareholder approval. Mr. Pankaj Kumar Gupta, currently President – Operations and a 17-year company veteran, was elevated to Executive Director for a five-year term. Additionally, 3,400 stock options were granted under ESOP 2020 at ₹100 per share, and M/s Jai Prakash & Company was re-appointed as Cost Auditor for FY25-26.
A strong quarter with double-digit profit growth signals healthy operating momentum for shareholders. The internal elevation of a long-serving operations head to Executive Director and continuity in independent directors are likely to be viewed as stability-positive, with no governance red flags.